01 / 08
Arrow keys or space to navigate
The vision
AI will solve health problems humans cannot solve.
For success, it needs proprietary biointelligence
at scale.
The focus
Kyora targets IP that generates unique biointelligence and a product opportunity.
The ideal
Therefore, held companies have two revenue categories.
Products and compounding intelligence.
Product Revenue
Product sales
License fees
Royalty income
Milestone payments
Distribution revenue
Compounding Intelligence Revenue
Data licensing
Model-training access
Analytics subscriptions
API usage fees
Partner-funded programs
The Strategy
Kyora moves breakthru science from research IP to exit with a 5 step strategy.
The Funnel
Major investment curated the science and recruited the talent.
This was not organic. Knight-backed investment helped concentrate world-class science and talent across UO and OHSU.
Seismic shift
AI biointelligence expands market capture.
More biology becomes solvable.
More companies become operable.
More value becomes captured.
TAMBroad AI-bio universe.
SAMAI-bio and data wedge.
SOMIllustrative 10-year Kyora platform capture case.
Summary
Kyora outcome:
Private equity-like ownership.
Venture capital-like upside.
1AI can solve health problems humans cannot solve alone. The future is rapid commercialization of solutions to human health problems.
2This data will generate massive new revenues through new productization and model training.
3Oregon has a concentration of untapped potential human health solutions from a ~$3B Knight investment.
4A strong operationalizing model is missing from the Oregon ecosystem. Kyora fills this gap.
5Kyora held companies will bring new levels of improved health to humanity.
6Kyora expands what is solvable, operable, and the total captured revenue.